Identifying HCV genotype 1 patients at risk of relapse

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 5, 2010, Pages 546-551

  Deschênes, Marc ^a   Bain, Vincent G ^b   Lee, Samuel S ^c   Sherman, Morris ^d   Cooper, Curtis L ^e   Yoshida, Eric M ^h   Marotta, Paul J ^f   Krajden, Mel ⁱ   Usaty, Christopher ^g   Balshaw, Robert ^j   Peltekian, Kevork M ^k  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g Roche   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^j Syreon Corporation   (Canada)

^k DALHOUSIE UNIVERSITY   (Canada)

more..

Author keywords

Chronic hepatitis C; Genotype 1; Peginterferon; Relapse; Ribavirin; Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNICITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE DIFFERENCE; RELAPSE; RETROSPECTIVE STUDY; SERUM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGE DISTRIBUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; RNA, VIRAL;

EID: 77951292686     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832d237d     Document Type: Article

References (22)

1. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130:231-264.
2. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
5. Hadziyannis SJ, Sette Jr. H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
6. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954-960.
7. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
8. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451-460.
9. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46:1688-1694.
10. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189:964-970.
11. Lee SS, Bain VG, Peltekian K, Krajden M, Yoshida EM, Deschenes M, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23:397-408. (Pubitemid 43382020)
12. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102:2181-2188.
13. Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction versus pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005; 75:27-34.
14. Kuboki M, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, et al. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007; 22:645-652. (Pubitemid 46608384)
15. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48:1753-1760.
16. Yu ML, Dai CY, Huang JF, Chuang WL. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weightbased ribavirin exposure. Hepatology 2008; 48:1019-1020.
17. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47:43-50.
18. Marcellin P, Jensen D, Hadziyannis S, Ferenci P. Differentiation of early virological response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (Pegasys) and ribavirin (Copegus) [abstract no. 1308]. Hepatology 2007; 46:818A.
19. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131:1040-1048. (Pubitemid 44515099)
20. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
21. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5:124-129.
22. Bain VG, Lee SS, Peltekian K, Yoshida EM, Deschenes M, Sherman M, et al. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin. Aliment Pharmacol Ther 2008; 28:43-50.